Published in Adv Exp Med Biol on January 01, 1981
Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol (2010) 2.54
Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther (2008) 1.48
A Txnrd1-dependent metabolic switch alters hepatic lipogenesis, glycogen storage, and detoxification. Free Radic Biol Med (2013) 0.83
The proper use of acetaminophen. Paediatr Child Health (2011) 0.82
Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J (1975) 9.18
Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther (1973) 5.23
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology (1974) 4.32
A randomised trial of home-versus-hospital management for patients with suspected myocardial infarction. Lancet (1978) 4.12
Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther (1973) 3.89
Interim discharge summaries: how are they best delivered to general practitioners? Br Med J (Clin Res Ed) (1987) 3.64
Menopausal flushing: does oestrogen therapy make sense? Lancet (1976) 3.47
Self-poisoning: management of patients in Nottingham, 1976. Br Med J (1978) 3.24
N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci U S A (1984) 3.09
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Accumulation and elimination of poliovirus by the eastern oyster. Am J Epidemiol (1966) 2.58
Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet (1980) 2.53
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med (1976) 2.33
Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J (1980) 2.32
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest (1970) 2.29
RNA binding domain of telomerase reverse transcriptase. Mol Cell Biol (2001) 2.27
National organ matching and distribution service. Br Med J (1974) 2.22
Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology (2000) 2.22
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol (2001) 2.20
Effect of a pyrimidopyrimidine derivative on thrombus formation in the rabbit. Nature (1965) 2.19
Is nursing any business of doctors? A simple guide to the "nursing process". Br Med J (Clin Res Ed) (1984) 2.17
Early reporting of myocardial infarction: impact of an experiment in patient education. Br Med J (Clin Res Ed) (1982) 2.11
Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet (1997) 2.09
Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 2.02
Vascular and hepatocellular peroxynitrite formation during acetaminophen toxicity: role of mitochondrial oxidant stress. Toxicol Sci (2001) 2.00
Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci U S A (1971) 2.00
Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre-eclampsia. Br J Obstet Gynaecol (1991) 1.91
Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther (1973) 1.90
Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. Br Med J (1967) 1.85
Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet (1985) 1.84
An association between abo blood-group distribution and geographical differences in death-rates. Lancet (1977) 1.81
Effect of dipyridamole on human platelet behaviour. Lancet (1965) 1.79
Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther (1983) 1.79
Studies on the rate of reduction of hepatic microsomal cytochrome P-450 by reduced nicotinamide adenine dinucleotide phosphate: effect of drug substrates. Mol Pharmacol (1969) 1.76
Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J Biol Chem (1989) 1.75
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. Mol Pharmacol (1976) 1.73
Dexamethasone in acute stroke. Br Med J (1978) 1.73
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology (1999) 1.68
Is an information booklet for patients leaving hospital helpful and useful? BMJ (1989) 1.68
Biochemistry of drug oxidation and reduction by enzymes in hepatic endoplasmic reticulum. Adv Pharmacol (1966) 1.68
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA (1967) 1.67
Selective protein covalent binding and target organ toxicity. Toxicol Appl Pharmacol (1997) 1.66
What constitutes evidence on the dietary prevention of coronary heart disease? Cosy beliefs or harsh facts? Int J Cardiol (1984) 1.66
Changes in Michaelis and spectral constants for aniline in hepatic microsomes from phenobarbital-treated rats. Mol Pharmacol (1969) 1.62
Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet (1988) 1.62
The role of the interview in student selection. S Afr Med J (1978) 1.59
Immunohistochemical localization and quantification of the 3-(cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity. Am J Pathol (1991) 1.57
Autumn Books: Who needs Clinical Pharmacology? Br Med J (Clin Res Ed) (1984) 1.57
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk. Br Med J (Clin Res Ed) (1982) 1.55
Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med (1996) 1.55
Effect of aggregating agents on the electrophoretic mobility of human platelets. Br Med J (1966) 1.55
Prevention and diagnosis of venous thrombosis in patients with hip fractures. A survey of current practice. Lancet (1976) 1.52
Blood pressure reduction in elderly: a randomised controlled trial of methyldopa. Br Med J (Clin Res Ed) (1981) 1.52
Effect of oestrogens on human platelet behaviour. Lancet (1968) 1.49
Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther (2008) 1.48
Low dose beta blockade in acute stroke ("BEST" trial): an evaluation. Br Med J (Clin Res Ed) (1988) 1.47
Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol (1999) 1.46
Use of isolated perfused organs in hypoxia and ischemia/reperfusion oxidant stress. Methods Enzymol (1990) 1.46
Patients' and general practitioners' satisfaction with information given on discharge from hospital: audit of a new information card. BMJ (1989) 1.45
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology (1974) 1.43
Studies on the destruction of liver microsomal cytochrome P-450 by carbon tetrachloride administration. Biochem Pharmacol (1968) 1.43
Loss of nuclear p53 protein in preneoplastic rat hepatocytes is accompanied by Mdm2 and Bcl-2 overexpression and by defective response to DNA damage in vivo. Hepatology (2000) 1.42
Progress in hepatology. Metabolic activation of drugs to toxic substances. Gastroenterology (1975) 1.42
Reactive oxygen species during ischemia-reflow injury in isolated perfused rat liver. J Clin Invest (1988) 1.38
Parent and peer attachment in early adolescent depression. J Abnorm Child Psychol (1990) 1.38
Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol (1993) 1.38
Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science (1976) 1.38
Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging (2000) 1.37
Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther (1997) 1.37
Primary immunolocalization of estrogen and progesterone target cells in the human anterior cruciate ligament. J Orthop Res (1996) 1.37
Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology (1995) 1.36
Anticoagulants in coronary heart disease--retrospect and prospect. Lancet (1981) 1.36
Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol (1991) 1.35
The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol (1991) 1.35
Platelet behaviour and drugs used in cardiovascular disease. Cardiovasc Res (1967) 1.32
Abnormalities in platelet behaviour in acute illnesses. Br Med J (1966) 1.31
Treatment of high blood pressure: should clinical practice be based on results of clinical trials? Br Med J (Clin Res Ed) (1986) 1.31
Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest (1983) 1.31